KinasepKipred: A Predictive Model for Estimating Ligand-Kinase Inhibitor Constant (pKi).
KC, G.; Hassan, M. M.; Sirimulla, S.
Show abstract
Kinases are one of the most important classes of drug targets for therapeutic use. Algorithms that can accurately predict the drug-kinase inhibitor constant (pKi) of kinases can considerably accelerate the drug discovery process. In this study, we have developed computational models, leveraging machine learning techniques, to predict ligand-kinase (pKi) values. Kinase-ligand inhibitor constant (Ki) data was retrieved from Drug Target Commons (DTC) and Metz databases. Machine learning models were developed based on structural and physicochemical features of the protein and, topological pharmacophore atomic triplets fingerprints of the ligands. Three machine learning models [random forest (RFR), extreme gradient boosting (XGBoost) and artificial neural network (ANN)] were tested for model development. The performance of our models were evaluated using several metrics with 95% confidence interval. RFR model was finally selected based on the evaluation metrics on test datasets and used for web implementation. The best and selected model achieved a Pearson correlation coefficient (R) of 0.887 (0.881, 0.893), root-mean-square error (RMSE) of 0.475 (0.465, 0.486), Concordance index (Con. Index) of 0.854 (0.851, 0.858), and an area under the curve of receiver operating characteristic curve (AUC-ROC) of 0.957 (0.954, 0.960) during the internal 5-fold cross validation.\n\nAvailabilityGitHub: https://github.com/sirimullalab/KinasepKipred, Docker: sirimullalab/kinasepkipred\n\nImplementationhttps://drugdiscovery.utep.edu/pki/\n\nGraphical TOC Entry O_FIG_DISPLAY_L [Figure 1] M_FIG_DISPLAY C_FIG_DISPLAY
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Retro Drug Design: From Target Properties to Molecular Structures 95%
- Streamlining Computational Fragment-Based Drug Discovery through Evolutionary Optimization Informed by Ligand-Based Virtual Prescreening 94%
- Advancements in Ligand-Based Virtual Screening through the Synergistic Integration of Graph Neural Networks and Expert-Crafted Descriptors 93%
Similar papers in this journal
- Machine learning enables accurate and rapid prediction of active molecules against breast cancer cells 93%
- Primary Target Prediction of Bioactive Molecules from Chemical Structure 91%
- Innovative, rapid, high throughput method for drug repurposing in a pandemic - a case study of SARS-CoV-2 and COVID-19 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.